Creso Pharma licensed to import its first medicinal cannabis product into Brazil

18 April 2019

Australia’s Creso Pharma (ASX: CPH) has received approval to import its first medicinal cannabis product into Brazil. Creso and its marketing partner, SIN Solution, have received regulatory clearance from Brazilian health regulatory agency ANVISA for the importation of Creso’s medicinal cannabis product cannaQIX 50.

cannaQIX 50 has been developed for patients suffering from chronic pain and, in particular, chronic pain related to neuropathic diseases such as multiple sclerosis, Parkinson’s and cancer.

The commercialization of cannaQIX 50 in Brazil follows the product’s successful launch in New Zealand last year. Sales and marketing efforts in Brazil will be supported by Creso’s established partnership with SIN Solution, which will also engage in the support of patients’ access with regards to regulatory authorities and insurers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK